‹ Back
Tirzepatide
What it is
Tirzepatide is a once weekly peptide that acts like two of your own gut hormones at the same time: GIP and GLP-1. Both are released from the small bowel after you eat and tell the brain, pancreas, stomach and fat tissue that food has arrived. Tirzepatide is built on the GIP backbone, with two Aib amino acids that stop the enzyme DPP-4 from cutting it, and a fatty acid tail that binds albumin so it stays in the blood for about five days. It is a metabolic signal, not a fat burner: it changes how hungry you are, how your body stores fuel and how your insulin works.
Sources
Read the original sources
- LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. (Coskun · 2018 · Abstract; full methods not assumed · checked 2026-10-13)
- Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. (Willard · 2020 · Abstract; full methods not assumed · checked 2026-10-13)
- SURMOUNT-1: tirzepatide and obesity (Jastreboff and colleagues · 2022 · Published abstract · checked 2026-10-08)
- Tirzepatide versus semaglutide once weekly in type 2 diabetes, Frias 2021, NEJM (Abstract · checked 2026-10-13)
- Tirzepatide for weight reduction in Chinese adults with obesity, Zhao 2024, JAMA (SURMOUNT-CN) (Abstract · checked 2026-10-13)
- Abdominal fat and metabolic markers on tirzepatide in Japanese people with obesity disease, Waki 2026, Endocrine Practice (SURMOUNT-J) (Abstract · checked 2026-10-13)
- A contemporary rationale for GIP receptor agonism in obesity, Samms 2025, Diabetes (Abstract · checked 2026-10-13)
- Semaglutide lowers body weight in rodents via distributed neural pathways (2020 · Abstract; rodent mechanism · checked 2026-10-13)
- Tirzepatide: unimolecular polypharmacology for obesity, 2025, Endocrinology: News, Opinions, Training (Russia) (Summary · checked 2026-10-13)
- Dual GIP/GLP-1 receptor agonist tirzepatide, the new incretin summit, 2026, Effective Pharmacotherapy (Russia) (Summary · checked 2026-10-13)
- History of drug treatment of obesity, Berkovskaya, Gurova, Surkova, Fadeev 2025, Problems of Endocrinology (Russia) (Summary · checked 2026-10-13)
- GLP-1 and dual GIP/GLP-1 receptor agonists: neuroendocrine mechanisms, Mysliwczyk 2026, Int J Mol Sci (Poland) (Abstract · checked 2026-10-13)
- Tirzepatide protocol, Peptide Dosing Protocols (Full text · checked 2026-10-13)